New drug quadruples three-year survival rates for mesothelioma in international trial
Mesothelioma survival rates have quadrupled over three years thanks to a drug that starves tumors of a key nutrient, marking the first successful new treatment combination for the disease in 20 years. The international ATOMIC-meso trial, led by Queen Mary University of London and published in JAMA Oncology, found that patients receiving pegargiminase alongside standard chemotherapy were significantly more likely to be alive three years later. The drug works by depleting arginine in the bloodstream, cutting off a nutrient that mesothelioma cells cannot produce themselves. For a cancer caused by asbestos exposure that has historically offered patients months rather than years, this breakthrough represents a genuine turning point.









